Meeting Minutes: Drug Formulary Committee

Date & Time: June 25, 2020; 5:30-9 PM
Minutes prepared by: Justin Johnson and Dave Hoang
Location: Virtual Meeting via Zoom

Attendance

- Members in attendance: Stacey Ness, PharmD.; Margaret Artz, RPh., PhD.; Monica Brands, RPh.; Al Heaton, PharmD.; Kyle Lehenbauer, MD.; Kathryn Lombardo, MD.; Kelly Ruby, PharmD.; Stuart Williams, J.D.; Mary Mescher Benbenek, APRN, PhD.; Ramona Powell, PharmD.; Michael Sprehe, MD.; James Phillips, MD.
- Members absent: None
- DHS staff present: Dave Hoang, PharmD., MBA; Chad Hope, PharmD.; Nathan Chomilo, MD.
- Others in attendance: Justin Johnson, PharmD.; Ariane Casey, PharmD; Tzuyin Kuo, Pharmacy Student

Report of the Chair

- Dr. Ness presided over the meeting. This is Dr. Ness’ last meeting with the committee as she is not seeking reappointment when her term expires on 8/23/2020.

Approval of Minutes

- Minutes from the March 2020 meeting were reviewed. No vote was taken to approve the minutes

DHS Housekeeping

- Uniform PDL maintenance
  - The committee recommended to the department by a unanimous vote that DFC review and recommendation are not needed to remove drugs from the Uniform PDL when the manufacturers of these drugs no longer participate in the federal drug rebate program.

Old Business – None

New Business

New Specialty Drugs for Continued PA

- The committee discussed Secuado and recommended to the department by a unanimous vote that Secuado remain on PA with the proposed criteria.
- The committee discussed Caplyta and recommended to the department by a unanimous vote that Caplyta remain on PA with the proposed criteria.
The committee discussed Palforzia and recommended to the department by a unanimous vote that Palforzia remain on PA with the proposed criteria, with the clarification on “patients > 18 years of age who met the initial criteria” for updosing phase and a typo correction to change the sentence from “Patient has not have experienced any treatment-restricting adverse effects” to “Patient has not experienced any treatment-restricting adverse effects.”

The committee discussed Ubrelvy and recommended to the department by a unanimous vote that Ubrelvy remain on PA with the proposed criteria.

The committee discussed Reyvow and recommended to the department by a unanimous vote that Reyvow remain on PA with the removal of “Medication overuse headache has been ruled out” from initial approval criteria.

The committee discussed Nurtec ODT and recommended to the department by a unanimous vote that Nurtec ODT remain on PA with the proposed criteria.

The committee discussed Vyepti and recommended to the department by a unanimous vote that Vyepti remain on PA with the following revisions to the criteria:

- Delete the first sub-bullet point of the 8th bullet of the “initial approval criteria” and add a bullet that states the following “Patient has had 4-7 migraine attacks with features consistent with migraine (with and/or without aura).”

**Existing specialty Drugs for Continued PA**

The committee discussed Botox and recommended to the department by a unanimous vote that Botox remain on PA with the proposed changes to existing criteria.

**New Drugs for Continued PA**

The committee discussed and recommended to the department by a unanimous vote that Annovera remain on PA with the following revisions to the criteria:

- Replace the 3rd bullet of the initial approval criteria with the following:
  - Prescriber attests that prescriber has reviewed and determined that the patient is not a candidate for the short-acting hormonal methods listed below:
    - Estrogen-progestin pill
    - Patch
    - 28-day cycle vaginal system

**Preferred drug list review**

- Antimigraine, Other therapeutic class- The committee discussed the Antimigraine, Other therapeutic class and recommended the following to the department by a unanimous vote:
  - AJOVY change from nonpreferred to preferred

- Antipsychotics therapeutic class- The committee discussed the Antipsychotics therapeutic class and recommended the following to the department by a unanimous vote:
  - FANAPT TABLET (ORAL) and FANAPT TITRATION PACK (ORAL) to change from preferred to nonpreferred
• SAPHRIS (SUBLINGUAL) ORAL to change from preferred to nonpreferred
• ABILIFY MYCITE (ORAL) to be added to the PDL as nonpreferred
• ARISTADA INITIO (INTRAMUSC) to be added to the PDL as nonpreferred
• CAPLYTA (ORAL) to be added to the PDL as nonpreferred
• PERSERIS (SUBCUTANE) to be added to the PDL as nonpreferred
• ZIPRASIDONE (INTRAMUSC) to be added to the PDL as nonpreferred
• SECUADO (TRANSDERMAL) to be added to the PDL as nonpreferred

• Antiviral, Oral therapeutic class - The committee discussed the Antiviral, Oral therapeutic class and recommended the following to the department by a unanimous vote:
  • TAMIFLU CAPSULE (ORAL) and TAMIFLU SUSPENSION (ORAL) to change from preferred to nonpreferred
  • XOFLUZA (ORAL) to be added to the PDL as nonpreferred
  • OSELTAMIVIR CAPSULE (ORAL) and OSELTAMIVIR SUSPENSION (ORAL) to be added to the PDL as preferred
  • RELENZA (INHALATION) to be added to the PDL as preferred

• Antiviral, Topical therapeutic class - The committee discussed the Antipsychotics therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antiviral, Topical drugs remain as presented.

• Beta-blockers- The committee discussed the Beta-blockers therapeutic class and recommended the following to the department by a unanimous vote:
  • KAPSPARGO (ORAL) to be added to the PDL as nonpreferred

• Bladder relaxant preparations therapeutic class - The committee discussed the Bladder relaxant preparations therapeutic class and recommended the following to the department by a unanimous vote:
  • OXYBUTYNIN ER (AG) (ORAL) to change from nonpreferred to preferred
  • SOLIFENACIN (ORAL) to change from nonpreferred to preferred
  • FLAVOXATE (ORAL) to be added to the PDL as nonpreferred

• Bone resorption suppression and related agents- The committee discussed the Bone resorption suppression and related agents and recommended to the department by a unanimous vote that the preferred and non-preferred Bone resorption suppression and related agents remain as presented.

• BPH therapeutic class- The committee discussed BPH therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred BPH therapeutic class remain as presented.

• Bronchodilators, beta agonist therapeutic class- The committee discussed the Bronchodilators, beta agonist therapeutic class and recommended the following to the department by a unanimous vote:
  • ALBUTEROL HFA (PROAIR HFA) (INHALATION) to be added to the PDL as preferred
  • PROAIR DIGIHALER (INHALATION) to be added to the PDL as nonpreferred

• Calcium channel blockers therapeutic class- The committee discussed Calcium channel blockers therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Calcium channel blockers therapeutic class remain as presented.

• Cephalosporins and related antibiotics- The committee discussed Cephalosporins and related antibiotics and recommended to postpone the review of the class to give the department time to research CDC guidelines and recommendations for the treatment of gonorrhea as well as to clarify regulation and its impact on CDC’s recommendation on expedited partner therapy.
• COPD therapeutic class- The committee discussed COPD therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred COPD therapeutic class remain as presented.

• Cytokine and CAM antagonists- The committee discussed Cytokine and CAM and recommended the following to the department by a unanimous vote:
  o RINVOQ ER (ORAL) to be added to the PDL as nonpreferred
  o ILARIS (SUBCUTANE,) and ILUMYA SYRINGE (SUBCUTANE,) to be added to the PDL as nonpreferred
  o AVSOLA (INJECTION) to be added to the PDL as nonpreferred
  o ACTEMRA AUTOINJECTOR (SUBCUTANE,) to be added to the PDL as nonpreferred

• Epinephrine, self-injected- The committee discussed Epinephrine, self-injected and recommended to the department by a unanimous vote that the preferred and non-preferred Epinephrine, self-injected remain as presented.

• Erythropoiesis stimulating proteins- The committee discussed Erythropoiesis stimulating proteins and recommended the following to the department by a unanimous vote:
  o EPOGEN (INJECTION) change from nonpreferred to preferred
  o RETACRIT (INJECTION) to be added to the PDL as preferred
  o PROCRIT (INJECTION) change from nonpreferred to preferred

• Fluoroquinolones, oral- The committee discussed Fluoroquinolones, oral class and recommended to the department by a unanimous vote that the preferred and non-preferred Fluoroquinolones, oral class remain as presented.

• Glucocorticoids, inhaled- The committee discussed Glucocorticoids, inhaled and recommended the following to the department by a unanimous vote:
  o ADVAIR DISKUS (INHALATION) change from nonpreferred to preferred
  o FLUTICASONE/SALMETEROL (ADVAIR) (AG) (INHALATION) change from nonpreferred to preferred
  o FLUTICASONE/SALMETEROL (ADVAIR) (INHALATION) to be added to the PDL as preferred
  o BUDESONIDE/FORMOTEROL (AG) (INHALATION) to be added to the PDL as non-preferred

• Growth hormone- The committee discussed Growth hormone class and recommended to the department by a unanimous vote that the preferred and non-preferred Growth hormone class remain as presented.

• HAE therapeutic class- The committee discussed HAE therapeutic class and recommended the following to the department by a unanimous vote:
  o TAKHZYRO (SUB-Q) to be added to the PDL as nonpreferred

• Hepatitis B therapeutic class- The committee discussed Hepatitis B therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Hepatitis B therapeutic class remain as presented.

• Intranasal rhinitis class- The committee discussed Intranasal rhinitis class and recommended to the department by a unanimous vote that the preferred and non-preferred Intranasal rhinitis class remain as presented.

• Leukotriene modifiers- The committee discussed Leukotriene modifiers class and recommended to the department by a unanimous vote that the preferred and non-preferred Leukotriene modifiers class remain as presented.

• Macrolides/ketolides- The committee discussed Macrolides/ketolides class and recommended to the department by a unanimous vote that the preferred and non-preferred Macrolides/ketolides class remain as presented.
## Adjournment

- Prior to adjournment, the committee recognized the contribution of our outgoing Chair, Stacey Ness, throughout the years. The committee then voted to elect Stuart Williams to be the new chair of the DFC.
- The meeting was adjourned at approximately 9:40 PM Central Time.